arrow
A

Andrea Rocca

University of Trieste
H指数:43
被引数:7,061

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study

探究针灸在管理乳腺癌患者围绝经期综合征有效性方面的生化标志物:FLAIR研究

2025-11-200
PRE
Existence and relevance of fulminant severe community-acquired pneumonia

暴发性重症社区获得性肺炎的存在及其相关性

2025-11-060
OAAI
Virtual Biomarkers and Simplified Metrics in the Modeling of Breast Cancer Neoadjuvant Therapy: A Proof-of-Concept Case Study Based on Diagnostic Imaging
2025-10-240
OA
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity

转移性乳腺癌患者循环肿瘤细胞的转录组学分析揭示了其生物学特征和表型异质性的新线索

2025-05-060
OA
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses

确定复发性/难治性胶质母细胞瘤的最佳治疗方案:一项包含多次贝叶斯网络荟萃分析的系统性综述

2024-12-012
OA
Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
2024-05-020
PRE
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study
CELLS
IF5.2
2024-03-290
OAAI
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F] Fluorodeoxyglucose PET/CT

骨转移的异质性是影响雌激素受体阳性乳腺癌患者预后的重要因素。[18F] 氟雌二醇PET/CT联合 [18F] 氟脱氧葡萄糖PET/CT的作用

2021-08-0121
OAAI
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)
2021-03-305
OA
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+and androgen receptor-positive metastatic or locally advanced breast cancer

恩扎鲁胺联合曲妥珠单抗治疗HER2和雄激素受体阳性转移性或局部晚期乳腺癌的疗效和安全性

2021-02-1623
OAAI
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
2021-02-0919
OAAI
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
2021-02-0115
OAAI